News

Fexapotide has completed 2 long-term large Phase 3 BPH studies‎ in the U.S. No other new prostate drug injectable currently in development has previously succeeded in enrolling and

The new investment, which is part of preferred-stock financing, increased AstraZeneca’s stake in Moderna to 9%. The British drugmaker first invested in Moderna in 2013. The agreement signed

The product was temporarily discontinued in April 2015 due to an issue concerning the active pharmaceutical ingredient supplier, which has been resolved. Ofloxacin otic is a quinolone antibiotic

Selumetinib was assessed in combination with docetaxel chemotherapy as a second-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). The phase

Scintilla's lead program is resiniferatoxin ("RTX") for the treatment of intractable cancer pain. SCILEX, based in Malvern, PA, is engaged in the development and commercialization of products focused

Known as INNO2VATE, the program consists of two studies designed to evaluate vadadustat in patients with anemia related to chronic kidney disease who are undergoing dialysis. Akebia's ongoing

The milestone, which triggered an undisclosed payment from Astellas, demonstrated that selective modulation of the Unfolded Protein Response (UPR) pathway in vitro is potentially an effective disease-modifying approach

The licensing, development and commercialization agreement is intended at rapidly advancing Pracinostat into phase III clinical development and expanding the treatment into further indications that include high-risk myelodysplastic

Tavocept is an investigational new drug candidate from BioNumerik’s portfolio that has shown potential for both oncology and non-oncology indications. Lantern Pharma is a Precision Oncology Medicine company